STAT stories you may have missed

The Congressional Research Service highlights the various ways Nancy Pelosi’s signature drug pricing plan could be found unconstitutional.

Here’s how White House Domestic Policy Council Director Joe Grogan shaped five of the Trump administration’s signature drug pricing proposals.

The FDA’s top drug regulator, Janet Woodcock, outlines a novel plan for dealing with drug shortages: public shaming.

Biogen raised lots of questions over its surprise Alzheimer’s announcement last week. Here’s STAT’s top seven burning questions.

A livestock-poison-turned-drug might save this woman from endless cancer surgeries. But if she helps test it, could she afford to keep taking it?

Normally, developing a new medicine takes 15 years. A new, highly effective cystic fibrosis drug came together — from synthesis in the lab to approval — in just three.